

## Personal Information

Email: yasin.kutlu@medipol.edu.tr

Web: <https://avesis.medipol.edu.tr/yasin.kutlu>

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer**  
KUTLU Y., Cekin R., AYDIN S., Shbair A. T. M., BİLİCİ A., Arici S., Oven B. B., AÇIKGÖZ Ö., Ozcan E., ÖLMEZ Ö. F., et al.  
Current Problems in Cancer, vol.50, 2024 (SCI-Expanded)
- II. **Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study**  
KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., Senocak Tasci E., Bas O., Dane F., SAKİN A., et al.  
Cancers, vol.16, no.12, 2024 (SCI-Expanded)
- III. **The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study**  
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., Şakalar T., Celayir Ö. M., KAYIKÇIOĞLU E., Aslan F., et al.  
International Journal of Clinical Oncology, vol.29, no.3, pp.258-265, 2024 (SCI-Expanded)
- IV. **Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide**  
Goktas Aydin S., Kutlu Y., Muglu H., Aydin A., Acikgoz Ö., Hamdard J., Karci E., Bilici A., Olmez Ö. F., Yildiz Ö.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.93, pp.71-78, 2024 (SCI-Expanded)
- V. **Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study**  
Taşçı E. Ş., KUTLU Y., ÖLMEZ Ö. F., Mutlu A. U., Gündoğdu Y., Seyyar M., Şahin E., ÇABUK D., Majidova N., Uğurlu İ., et al.  
Expert Opinion on Pharmacotherapy, vol.25, no.4, pp.477-484, 2024 (SCI-Expanded)
- VI. **Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms**  
Karaalioglu B., ÇAKIR T., KUTLU Y., ŞEKER M., BİLİCİ A.  
Abdominal Radiology, vol.49, no.1, pp.131-140, 2024 (SCI-Expanded)
- VII. **Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience**  
HAMDARD J., BİLİCİ A., Sakin A., Kahraman S., Yasin A. I., Kalaci E., Gokmen I., AÇIKGÖZ Ö., KUTLU Y., Sendur M. A. N., et al.  
Journal of Chemotherapy, 2024 (SCI-Expanded)
- VIII. **Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer**  
GÖKTAŞ AYDIN S., BİLİCİ A., ÇALIŞ E., KUTLU Y., HAMDARD J., MUĞLU H., Fatih Olmez Ö. F., KARCI E., AÇIKGÖZ Ö.  
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.124, 2023 (SCI-Expanded)
- IX. **Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients**

**with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy**

Kutlu Y., Aydın S. G., Bilici A., Oven B. B., Ölmez Ö. F., Açıkgöz Ö., Hamdard J.  
Medicine (United States), vol.102, no.15, 2023 (SCI-Expanded)

- X. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**  
Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Oven B. B., Uluç B. O., Demiray A. G., Erdem D., Demir B., et al.  
Journal of Cancer Research and Clinical Oncology, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- XI. **The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer**  
Aydın S. G., BİLİCİ A., ÖLMEZ Ö. F., OVEN B. B., AÇIKGÖZ Ö., ÇAKIR T., BASIM P., ÇAKIR A., KUTLU Y., HAMDARD J.  
Breast Care, vol.17, no.5, pp.470-479, 2022 (SCI-Expanded)

## Articles Published in Other Journals

- I. **The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data**  
AYDIN S., ÖLMEZ Ö. F., Selvi O., Geredeli C., ÖZDEN F., BİLİCİ A., AÇIKGÖZ Ö., KARCI E., KUTLU Y., HAMDARD J., et al.  
Journal of Gastrointestinal Cancer, vol.55, no.1, pp.227-236, 2024 (ESCI)
- II. **The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients**  
acıkgöz o., Göktaş Aydın S., Bilici A., Kutlu Y., Muglu H., Karcı E., J., Mammadov E., ÖLMEZ Ö. F., yıldız Ö.  
ACTA ONCOLOGICA TURCICA, vol.56, no.2, pp.153-160, 2023 (Peer-Reviewed Journal)
- III. **SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT**  
Aydın S., Kutlu Y., Muglu H., Açıkgöz Ö., Aydın A., Bilici A., Ölmez Ö. F., Unal D., Karcı E., Yıldız Ö.  
İstanbul Tıp Fakültesi Dergisi, vol.86, no.2, pp.117-122, 2023 (ESCI)
- IV. **Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock**  
Toprak I. D., Eruzun H., KUTLU Y., Arman Y., Yumustutan P., Yoldemir S. A., Akarsu M., Dikker O., Tukek T.  
Journal of Experimental and Clinical Medicine (Turkey), vol.39, no.1, pp.1-6, 2022 (Scopus)
- V. **Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer**  
AYDIN S. G., AÇIKGÖZ Ö., KUTLU Y., BİLİCİ A., HAMDARD J., ÖLMEZ Ö. F., YILDIZ Ö.  
ACTA ONCOLOGICA TURCICA, vol.54, no.3, pp.281-290, 2021 (Peer-Reviewed Journal)